Results 51 to 60 of about 4,744 (194)

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping

, 2022
Fluoropyrimidines (FP; 5-fluorouracil, capecitabine, and tegafur) are a commonly prescribed class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 million patients globally per annum.
Ziolkowski, A, Ackland, S, Mossman, D, White, C, Scott, RJ, Paul, C, Michael, M, Fox, SB   +7 more
core   +1 more source

Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience

Dose-Response, 2018
Background: Severe toxicity is experienced by a substantial minority of patients receiving fluoropyrimidine-based chemotherapy, with approximately 20% of these severe toxicities attributable to polymorphisms in the DPYD gene.
Con Murphy, Stephen Byrne, Gul Ahmed, Andrew Kenny, James Gallagher, Harry Harvey, Eoin O’Farrell, Brian Bird   +7 more
doaj   +1 more source

A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy

, 2012
Chemotherapeutic use of 5-fluorouracil (5FU) is compromised by 10-20% of patients developing severe toxicity. Recently described genetic variation in dihydropyrimidine dehydrogenase (DPYD) has been shown to be a major predictor of 5FU toxicity.
Largiadèr, Carlo R, Fu, Yung-Kang, Sistonen, Johanna, Smith, Chingying   +3 more
core   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis

BMC Cancer
Background Fluoropyrimidines are chemotherapy drugs utilized to treat a variety of solid tumors. These drugs predominantly rely on the enzyme dihydropyrimidine dehydrogenase (DPD), which is encoded by the DPYD gene, for their metabolism.
Francisco Cezar Aquino de Moraes, Alícia Batista de Almeida Barbosa, Vitor Kendi Tsuchiya Sano, Francinny Alves Kelly, Rommel Mario Rodriguez Burbano   +4 more
doaj   +1 more source

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen, Anne Kirstine Boas, Emilie Clausen, Nicoline Elers Koch, Anne Byriel Walls, Lotte Stig Nørgaard, Michael Asger Andersen, Anissa Aharaz, Rikke Lundsgaard Nielsen, Olivia Bornæs, Juliette Tavenier, Baker Nawfal Jawad, Helle Gybel Juul‐Larsen, Esben Iversen, Ove Andersen, Lona Louring Christrup, Kim Peder Dalhoff, Morten Baltzer Houlind   +17 more
wiley   +1 more source

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study

Pharmaceutics
Fluoropyrimidines (FPs) are commonly prescribed in many cancer streams. The EMA and FDA-approved drug labels for FPs recommend genotyping the DPYD*2A (rs3918290), *13 (rs55886062), *HapB3 (rs56038477), alleles, and DPYD rs67376798 before treatment starts.
Xando Díaz-Villamarín, María Martínez-Pérez, María Teresa Nieto-Sánchez, Gabriela Ruiz-Tueros, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, Antonio J. Iáñez, José Cabeza-Barrera, Rocío Morón   +10 more
doaj   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Head and Neck Lymph Node Metastases From Cancer of Unknown Primary: Outcomes From p16‐Guided Mucosal Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Background The AJCC 8th edition distinguishes p16‐positive oropharyngeal head and neck carcinoma of unknown primary (HNCUP) due to its superior prognosis. However, standardized radiation volume guidelines are lacking. This study evaluates the safety of p16‐guided mucosal volume reduction.
Philippe Harris, Dhiya‐Eddine Mabrouki, Felix‐Phuc Nguyen‐Tan, Edith Filion, Olivier Ballivy, Brian O'Sullivan, Apostolos Christopoulos, Tareck Ayad, Louis Guertin, Eric Bissada, Paul Tabet, Denis Soulières, Antoine Desilets, Alexandre Pellan Cheng, Robert Doucet, Laurent Létourneau‐Guillon, Houda Bahig   +16 more
wiley   +1 more source

Mutations at codon 974 of the DPYD gene are a rare event [PDF]

British Journal of Cancer, 1997
A mutation at codon 974 of the dihydropyrimidine dehydrogenase (DPD) gene was previously described in a cancer patient with undetectable DPD enzyme activity who experienced severe toxicity when treated with 5-fluorouracil. We have studied the frequency of this mutation in 29 Scottish subjects with low DPD enzyme activity and in 274 American subjects ...
S A, Ridge, O, Brown, J, McMurrough, P, Fernandez-Salguero, W E, Evans, F J, Gonzalez, H L, McLeod   +6 more
openaire   +2 more sources